stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
128.36 | 0.00 | 0.00 | 0.00 |
P/S ratio |
5.41 | 5.44 | 5.56 | 6.40 | |
P/FCF ratio |
0.00 | 207.39 | 0.00 | 0.00 | |
P/Operating CF |
(112.14) | 200.15 | (39.65) | (195.68) | |
P/B ratio |
10.59 | 4.65 | 4.65 | 5.39 | |
Price to Tangible BV |
11.51 | 4.81 | 4.81 | 5.57 | |
EV/Sales |
4.66 | 5.06 | 4.97 | 5.83 | |
EV/EBITDA |
38.79 | 235.25 | 0.00 | 0.00 | |
EV/Operating CF |
537.99 | 137.05 | (120.29) | (30.65) | |
EV/FCF |
(615.37) | 192.86 | (83.33) | (27.91) | |
Quick Ratio |
5.21 | 3.68 | 3.59 | 0.00 | |
Current Ratio |
6.28 | 4.64 | 4.26 | 4.32 | |
Net Debt/EBITDA |
(17.74) | 5.74 | 5.80 | — | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | — | |
Asset Turnover |
0.68 | 0.80 | 0.68 | 0.68 | |
Operating CF/Net income |
3.26 | (0.37) | 1.43 | 0.98 | |
Capex/Depreciation |
(0.19) | (0.26) | (0.87) | 0.00 | |
Interest Coverage |
— | — | (15.23) | — | |
Research and Development Expense of Revenue |
(0.30%) | 29.92% | 65.75% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
75.46% | 94.84% | 74.29% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.02 | 0.00 | |
Share Based Compensation of Revenue |
12.36% | 11.47% | 7.13% | 5.27% | |
Graham Net Nets |
0.19 | 0.10 | 0.13 | 0.11 | |
Graham Number |
0.91 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.78% | (1.08%) | (3.03%) | (3.82%) | |
Free Cash Flow Yield |
(0.14%) | 0.48% | (1.07%) | (3.26%) | |
Revenue per Share |
0.42 | 0.25 | 0.29 | 0.31 | |
Operating CF per Share |
(0.06) | 0.03 | (0.17) | (0.04) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.06) | 0.03 | (0.18) | (0.04) | |
Cash per Share |
1.04 | 0.55 | 0.74 | 0.00 | |
Shareholders Equity per Share |
2.11 | 1.50 | 1.64 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.11 | 1.50 | 1.64 | 0.00 | |
Free Cash Flow |
(5.75) | 3.00 | (18.01) | (4.08) | |
Working Capital |
125.58 | 71.94 | 93.41 | 94.82 | |
Capital Expenditures |
(0.13) | (0.18) | (1.28) | (0.10) | |
Net Current Asset Value |
117.96 | 66.70 | 87.74 | 88.22 | |
EV/EBIT |
47.30 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.04 | 0.00 | |
Price to Operating Income |
54.91 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
28.04 | 21.69 | 26.44 | — | |
Average Payables |
0.72 | 0.19 | 0.65 | 1.60 | |
Average Inventory |
8.25 | 9.62 | 10.14 | 10.54 | |
Average Assets |
172.58 | 145.90 | 175.95 | 180.32 | |
Average Common Equity |
78.97 | 120.64 | 135.97 | 140.97 |
Columns are period end dates · fundamentals updated 6 Nov 2026